Anthrax Vaccine Global Market Report 2026

The anthrax vaccine is a medical product developed to induce immunity against anthrax, a serious infectious disease caused by the bacterium Bacillus anthracis. The vaccine contains an inactivated form of the anthrax bacterium or its components, prompting the body's immune system to generate antibodies against anthrax toxins. The anthrax vaccine is usually given through injections, starting with initial doses followed by booster shots to sustain immunity over time.

The main vaccine types of the anthrax vaccine include the cell-free protective antigen (PA) vaccine and the live attenuated vaccine. A cell-free protective antigen (PA) vaccine is produced in a laboratory without using live bacteria by synthesizing the protective antigen (PA) protein of the anthrax bacteria. Its applications cover both animal and human use, and it is distributed through various channels such as hospitals, pharmacies, and others.

Tariffs have impacted the anthrax vaccine market by increasing the cost of imported raw materials and laboratory equipment, leading to higher production expenses. Vaccine segments such as cell-free protective antigen (PA) vaccines and live attenuated vaccines are most affected, particularly in regions like North America and Europe where import dependency is higher. While tariffs may slow market expansion in some areas, they also incentivize local manufacturing and investment in domestic vaccine production capabilities, potentially enhancing supply chain resilience and long-term market stability.

The anthrax vaccine market research report is one of a series of new reports from The Business Research Company that provides anthrax vaccine market statistics, including anthrax vaccine industry global market size, regional shares, competitors with a anthrax vaccine market share, detailed anthrax vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the anthrax vaccine industry. This anthrax vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anthrax vaccine market size has grown steadily in recent years. It will grow from $11.77 billion in 2025 to $12.33 billion in 2026 at a compound annual growth rate (CAGR) of 4.7%. The growth in the historic period can be attributed to high prevalence of anthrax in livestock, government-led vaccination campaigns, research in immunology, limited vaccine production capacity, increased awareness of occupational exposure.

The anthrax vaccine market size is expected to see steady growth in the next few years. It will grow to $14.49 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to development of recombinant and next-generation vaccines, rising demand for human and animal prophylaxis, advancements in vaccine delivery technologies, expansion of biodefense programs, collaborations between pharma and defense sectors. Major trends in the forecast period include advanced vaccine formulations, expanded immunization programs, cold chain & storage innovations, biodefense & pandemic preparedness, government & military vaccination initiatives.

The increasing prevalence of infectious diseases is expected to drive the growth of the anthrax vaccine market in the coming years. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi, which can be transmitted directly or indirectly from one person to another, often resulting in symptoms that range from mild to severe and, in some cases, fatal, depending on the pathogen and the individual's immune response. The rise in infectious diseases is attributed to shifts in global population demographics, urbanization, environmental and land use changes, and alterations in human behavior. The anthrax vaccine is primarily used to protect against anthrax, and its potential for wider application in preventing other infectious diseases is being investigated through research on its immunogenic properties and adaptability. For example, in February 2023, the Council on Foreign Relations, a US-based nonprofit organization, reported that up to 75% of newly identified or emerging infectious diseases (EIDs) and 60% of recognized infectious diseases originated from zoonotic sources. Globally, zoonoses are responsible for 2.7 million human deaths and 2.5 billion cases of disease in people each year. Consequently, the growing prevalence of infectious diseases is fueling the expansion of the anthrax vaccine market.

Major companies operating in the anthrax vaccine market are concentrating on developing innovative products and obtaining FDA approvals for their vaccines to ensure safety, efficacy, and availability for individuals at risk of anthrax exposure. FDA approval guarantees that the vaccine undergoes rigorous testing in clinical trials and is proven safe for public use. This process helps protect individuals from potential adverse effects. For example, in July 2023, Emergent BioSolutions Inc., a US-based biopharmaceutical company, received approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), formerly known as AV7909, from the U.S. Food and Drug Administration (FDA). The approval was based on data from a Phase 2 trial assessing Cyfendus's non-interference with antibacterial medications and Phase 3 clinical research comparing the immunogenicity and safety of the vaccine to BioThrax, the previous anthrax vaccine. Additionally, developing safer and more effective adjuvants is essential to address reactogenicity-related issues and improve the overall effectiveness of anthrax vaccines.

In April 2025, Green Cross Corporation, a South Korea-based biopharmaceutical company that develops anthrax and other vaccines and biologics, collaborated with the Korea Disease Control and Prevention Agency (KDCA) for the development and approval of a recombinant anthrax vaccine. Through this collaboration, GC Biopharma and KDCA aim to combine their expertise in biotechnology and public health, integrating GC Biopharma's recombinant-protein vaccine technology with KDCA's regulatory and disease prevention capabilities to deliver a safe and effective anthrax vaccine, ultimately enhancing national biodefense preparedness. The Korea Disease Control and Prevention Agency (KDCA) is a South Korea-based government agency responsible for disease control, prevention, and public health management.

Major companies operating in the anthrax vaccine market are Emergent BioSolutions Inc., Indian Immunologicals Limited, GC Biopharma, Valneva SE, PharmAthene Inc., Porton Biopharma Limited, Choong Ang Vaccine Laboratories Co. Ltd., Colorado Serum Company Inc., Botswana Vaccine Institute, VECOL S.A., Biological E Limited, Serum Institute of India Pvt. Ltd., Panacea Biotec Ltd., China National Biotec Group, Sinovac Biotech Ltd., Instituto Butantan, Razi Vaccine and Serum Research Institute, Federal State Unitary Enterprise Microgen, KM Biologics Co. Ltd., Haffkine Bio-Pharmaceutical Corporation Ltd.

North America was the largest region in the anthrax vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anthrax vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anthrax vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anthrax vaccine market consists of sales of avirulent, nonencapsulated bacillus anthracis microaerophilic cultures, aluminum, benzethonium chloride, and formaldehyde. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anthrax Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses anthrax vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anthrax vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anthrax vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Vaccine Type: Cell-Free Protective Antigen (PA) Vaccine; Live Attenuated Vaccine
• 2) By Application Type: Animal Use; Human Use
• 3) By Distribution Channel: Hospitals; Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Cell-Free Protective Antigen (PA) Vaccine: Recombinant Protective Antigen (rPA) Vaccine; Adjuvanted rPA Vaccine
• 2) By Live Attenuated Vaccine: Live Attenuated Bacillus anthracis Vaccine; Genetically Modified Live Attenuated Vaccine
• Companies Mentioned: Emergent BioSolutions Inc.; Indian Immunologicals Limited; GC Biopharma; Valneva SE; PharmAthene Inc.; Porton Biopharma Limited; Choong Ang Vaccine Laboratories Co. Ltd.; Colorado Serum Company Inc.; Botswana Vaccine Institute; VECOL S.A.; Biological E Limited; Serum Institute of India Pvt. Ltd.; Panacea Biotec Ltd.; China National Biotec Group; Sinovac Biotech Ltd.; Instituto Butantan; Razi Vaccine and Serum Research Institute; Federal State Unitary Enterprise Microgen; KM Biologics Co. Ltd.; Haffkine Bio-Pharmaceutical Corporation Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.